mk 0663 has been researched along with Rheumatism in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Micu, MC; Micu, R; Ostensen, M | 1 |
| Krüger, K | 1 |
| Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S | 2 |
| Einecke, D | 1 |
| Baraf, HS | 1 |
2 review(s) available for mk 0663 and Rheumatism
| Article | Year |
|---|---|
[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Etoricoxib; Gout; Humans; Osteoarthritis; Placebos; Pyrazoles; Pyridines; Rheumatic Diseases; Spondylitis, Ankylosing; Sulfonamides; Sulfones | 2005 |
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Hemorrhage; Humans; Membrane Proteins; Osteoarthritis; Patient Selection; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Spondylitis, Ankylosing; Sulfones | 2007 |
2 trial(s) available for mk 0663 and Rheumatism
| Article | Year |
|---|---|
The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Tract; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Pyridines; Rheumatic Diseases; Severity of Illness Index; Sulfones; Treatment Outcome | 2006 |
Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocation Tests; Cross Reactions; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Dyspnea; Etoricoxib; Female; Forced Expiratory Volume; Humans; Male; Peak Expiratory Flow Rate; Pyridines; Rheumatic Diseases; Single-Blind Method; Sulfones | 2006 |
2 other study(ies) available for mk 0663 and Rheumatism
| Article | Year |
|---|---|
Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Chi-Square Distribution; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Fertility; Humans; Ibuprofen; Infertility, Female; Inflammation; Norway; Ovarian Follicle; Ovulation; Pregnancy; Prospective Studies; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Sulfones; Ultrasonography | 2011 |
[By what means does the rheumatic patient with gastrointestinal risks fare best?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Controlled Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Diseases; Germany; Humans; Naproxen; Osteoarthritis; Proton Pump Inhibitors; Pyridines; Rheumatic Diseases; Risk Factors; Sulfones; United States | 2007 |